newsfilter
← Latest News
PR Newswire·

Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study evaluating SEL-212 for chronic refractory gout

STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ:SELB), today announced the completion of enrolment for DISSOLVE I, the first of two clinical studies of the phase 3 DIS